NEW YORK--(BUSINESS WIRE)--
Pfizer Inc. today announced the election of Dr. Dan R. Littman to its
Board of Directors. Dr. Littman, age 65, was also appointed to the
Corporate Governance and Science and Technology Committees of Pfizer’s
Board.
Dr. Littman is the Helen L. and Martin S. Kimmel Professor of Molecular
Immunology at the Skirball Institute of Biomolecular Medicine of NYU
Langone Medical Center and an Investigator of the Howard Hughes Medical
Institute. Prior to joining NYU in 1995, he was a Professor of
Microbiology and Immunology at the University of California, San
Francisco.
Dr. Littman is also a member of the National Academy of the Sciences and
the Institute of Medicine, and is a Fellow of the American Academy of
Arts and Sciences and the American Academy of Microbiology.
Dr. Littman received an A.B. in Biochemical Sciences from Princeton
University and an M.D. and Ph.D. from Washington University School of
Medicine.
“We are pleased to welcome a renowned immunologist to Pfizer’s Board of
Directors,” said Ian Read, Chairman and Chief Executive Officer, Pfizer.
“Dr. Littman has made extraordinary scientific contributions throughout
his career and will be a tremendous asset to the company. The addition
of Dan to the board helps to ensure that Pfizer will continue to benefit
from a breadth and diversity of experience.”
About Pfizer Inc.
At Pfizer, we apply science and our global resources to bring therapies
to people that extend and significantly improve their lives. We strive
to set the standard for quality, safety and value in the discovery,
development and manufacture of health care products. Our global
portfolio includes medicines and vaccines as well as m any of the
world's best - known consumer health care products. Every day, Pfizer
colleagues work across developed and emerging markets to advance
wellness, prevention, treatments and cures that challenge the most
feared diseases of our time. Consistent with our responsibility as one
of the world's premier innovative biopharmaceutical companies, we
collaborate with health care providers, governments and local
communities to support and expand access to reliable, affordable health
care around the world. For more than 150 years, we have worked to make a
difference for all who rely on us. We routinely post information that
may be important to investors on our website at www.pfizer.com.
In addition, to learn more, please visit us on www.pfizer.com
and follow us on Twitter at @Pfizer
and @Pfizer_News,
LinkedIn,
YouTube
and like us on Facebook at Facebook.com/Pfizer.
View source version on businesswire.com: http://www.businesswire.com/news/home/20180305006056/en/
Source: Pfizer Inc.